Earnings results for Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma A/S is expected* to report earnings on 11/11/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.8. The reported EPS for the same quarter last year was $-0.59.
Ascendis Pharma A/S last announced its quarterly earnings data on August 27th, 2020. The biotechnology company reported ($1.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.31. The firm earned $1.58 million during the quarter, compared to analyst estimates of $2.47 million. Ascendis Pharma A/S has generated ($5.25) earnings per share over the last year. Ascendis Pharma A/S has confirmed that its next quarterly earnings report will be published on Wednesday, November 11th, 2020.
Analyst Opinion on Ascendis Pharma A/S (NASDAQ:ASND)
11 Wall Street analysts have issued ratings and price targets for Ascendis Pharma A/S in the last 12 months. Their average twelve-month price target is $175.45, predicting that the stock has a possible upside of 8.59%. The high price target for ASND is $208.00 and the low price target for ASND is $145.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Ascendis Pharma A/S has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $175.45, Ascendis Pharma A/S has a forecasted upside of 8.6% from its current price of $161.58. Ascendis Pharma A/S has only been the subject of 4 research reports in the past 90 days.
Dividend Strength: Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma A/S does not currently pay a dividend. Ascendis Pharma A/S does not have a long track record of dividend growth.
Insiders buying/selling: Ascendis Pharma A/S (NASDAQ:ASND)
In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock. 40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health. 91.39% of the stock of Ascendis Pharma A/S is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Ascendis Pharma A/S (NASDAQ:ASND
Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($7.24) to ($7.07) per share. The P/E ratio of Ascendis Pharma A/S is -26.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Ascendis Pharma A/S is -26.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Ascendis Pharma A/S has a P/B Ratio of 10.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here